ijddr

International Journal of Drug Development and Research

ISSN - 0975-9344

- (2013) Volume 5, Issue 2

View PDF Download PDF

Sedative, Anxiolytic and Anticonvulsant effects of different extracts from the leaves of Ipomoea Carnea in experimental Animals

 

Author info »

Abstract

The objective of this study is to investigate the sedative, anxiolytic and anticonvulsant activities of different leaf extracts of Ipomoea carnea. Materials and methods: The sedative effect of the different leaf extracts at dose level 100, 200 and 400 mg/kg was evaluated in mice and rats using phenobarbitone induced sleeping time and hole board models. Its anxiolytic effect was evaluated using the Evaluated Plus Maze (EPM) and the Y maze (YM) methods. The anticonvulsant activity was evaluated in mice and rats using the strychnine, picrotoxin and MES-induced seizure models. The acute toxicity studies and phytochemical analysis of the extract were also carried out. Results: The methanolic and aqueous extracts ) produced significant (P < 0.01) reduction in the time of onset of sleep induced by phenobarbitone. The prolongation of phenobarbitone sleeping time by the extract (200 mg/kg) was comparable to that produced by diazepam (4 mg/kg). At doses of 100–400 mg/kg, the extract produced a dose dependent decrease in exploratory activity of the mice. The reduction in exploratory activity produced by the extract (400 mg/kg) was greater than that of chlorpromazine. The results obtained from the experiments indicate that the extract has central nervous system depressant and anxiolytic activities. In anxiolytic effect the extracts showed dose dependent prolongation of the cumulative time spent in the open arms of the elevated plus maze and Y maze compared with the control. It also produced a significant (P < 0.01) dose dependent increase in onset of convulsion compared to the control for strychnine, picrotoxin and MES -induced seizures. The LD50 obtained for the acute toxicity studies using oral route of administration was 3000 mg/kg respectively. Conclusion: These findings justify the use of Ipomoea carnea in traditional medicine for the management of convulsion and psychosis.

References Blog | Places to Visit in Belgium Casino Sites in New Zealand Blog | Places to Visit in Brazil Cardiology Articles Blog | Places to Visit in Canada Find Lawyer in Massachusetts Find Lawyer in Wisconsin Blog | Places to Visit in Czech Republic Find Lawyer in North Carolina Blog | Places to Visit in Germany Best Betting Sites in United Kingdom Blog | Places to Visit in Egypt Best Betting Sites in South Africa Blog | Places to Visit in Spain Casino Sites in United Arab Emirates Blog | Places to Visit in France Vehicle Technologies Articles Blog | Places to Visit in Greece Real Estate in Europe Blog | Places to Visit in Hong Kong

References

  1. Thomas, R., Christopher, D., 2004. Evolution of insomnia: current status and future direction. Sleep Medicines 5, S23–S30.
  2. Kessler RC,Chinu WT, Demler O. Prevalence, severity and co-morbidity of 12-month DSM-IV disorders in the national Co-morbidity survey Replication.Arch Gen Psychiatry 2005; 62:617-27.
  3. Kasper S.SocialPhobia;The nature of the disorder.J affect disord 1998:50; S3-9.
  4. Baldessarini R. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, editors. Goodman and Gillman’s The pharmacological Basis of Therapeutics. 10th ed. Newyork; McGraw-Hill;2001. 399-427.
  5. Suresh K, Anupam S, Apigenin: The anxiolytic constituent of Tumeraaphrodisiaca.PharmBiol 2006; 44: 84-90.
  6. Goodman and Gilman’s. The pharmacological basis of therapeutics. In: James O. McNamara, editors, Pharmacotherapy of the epilepsies 11thed. New York: McGrawi Hill publishers; 2001. p. 501-525.
  7. Duraisami R, Srinivasan D, Ramaswamy S. Anticonvulsant activity of bioflavonoid gossypin. Bangaladesh J Pharmacol 2009; 4 :51-54.
  8. Mattson RH. Drug treatment of partial epilepsy.AdvNeurol 1992; 57:643-650.
  9. Gupta YK, Malhotra J. Adenosinergic system as an endogenous anticonvulsant mechanism. J Physilol and Pharmacol 1997; 41:329-343
  10. Austin, D. F. Ipomoea carneaJacq. v. Ipomoea fistulosaMart.exChoisy. Taxon 1977, 26, 235-238.
  11. Idris, O. F.; Tartour, G.; Adam, S. E. I.; Obeid, H. M. Toxicity to goats of Ipomoea carnea. Trop. Anim. Health Prod. 1973, 5, 119-123.
  12. Tirkey, K.; Yadava, K. P.; Mandal, T. K. Effect of aqueous extract of Ipomoea carnea on the haematological and biochemical parameters in goats. Indian J. Anim. Sci. 1987, 57, 1019-1023.
  13. Damir, H. A.; Adam, S. E.; Tartour, G. The effects of Ipomoea carnea on goats and sheep. Vet. Hum. Toxicol.1987, 29, 316- 319.
  14. De Balogh, K. K. I. M.; Dimande, A. P.; van der Lugt, J. J.; Molyneux, R. J.; Naude´, T. W.; Welman, W. G. A lysosomal storage disease induced by Ipomoea carnea in goats in Mozambique. J. Vet. Diagn.InVest. 1999, 11, 266-273.
  15. Asano, N.; Kato, A.; Oseki, K.; Kizu, H.; Matsui, K. Calystegins of Physalisalkekengi var. francheti (Solanaceae). Structure determination and their glycosidase inhibitory activities. Eur. J. Biochem. 1995, 229, 369-376.
  16. Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R. J. Polyhydroxylatedalkaloidssnatural occurrence and therapeutic applications. Phytochemistry 2001, 56, 265-295.
  17. http:\www.\Ipomoea Carnea, Ipomoea Carnea Leaves, Leaves of Ipomoea Carnea, Ipomoea Carnea from India.htm.
  18. Ríos E., Cholich L., Silva J., and Acosta de Pérez. “Histopathological lesions in central nervous system of goats poisoned by Ipomoea carnea.” Rev. Vet. 19: 2, 130–134, 2008.
  19. Gaur Kalpesh.,Kori M.L., Tyagi L.K., Nema R.K., Sharma C.S. and TripathiPriyanka. “In-vitro Antioxidant Activity of Leaves of Ipomoea fistulosa Linn.” Academic Journal of Plant Sciences 2 (2): 60-64, 2009.
  20. Jain R, Jain N, Jain S. Evaluation of antiinflammatory activity of ipomoea fistulosalinn. Asian Journal of Pharmaceutical and Clinical Research. (II): Issue 1, 64-67, 2009.
  21. Burger G T and Miller C L, Animal care and facilities, in Principles and methods of toxicology, 2nd ed., (Wallace Hayes A, Raven Press Ltd. New York), 1989, 527.
  22. Goyal R K, Practicals in Pharmacology, 3rd ed. (SahPrakashan, Ahmedabad), 2002, 7.
  23. Kokate CK: A Text Book of Practical Pharmacognosy. VallabhPrakasham, New Delhi,tenth edition,1994:112-120.
  24. Jayaraman J: Laboratory Manual in Biochemistry. New age international (p) Ltd, 1st Edition 1981,13.
  25. Litchfield JT and Wilcoxon F. 1949.A simplified method of evaluating dose effect experiments. J PharmacolExpTher. 96: 99-113.
  26. Lipnick RL, Cottruvo JP, Hill RN, Brucce RD, Stitzel KA, Walker AP, et al. Comparision of the up-anddown, conventional LD50, and fixed dose acute toxicity procedures. Food ChemToxicol 1995; 33:223-31.
  27. Dixit VK, Verma KC, Effects of essential oil of leaves of Blumealacera DC on central nervous system., Indian J. Pharmacol, 1976, 18, 7.
  28. Turner RA (ed). Screening methods in pharmacology. New York, Academic Press, 1965: 26–35.
  29. DandiyaPC and Collumbine.Studies on Acoruscalamus (III): some pharmacological action of the volatile oil. J PharmacolExpTher. 1959,125: 353-359 .
  30. R. A. Turner, Screening Procedure in Pharmacology, Academic Press, New York 1972, 1st ed., 78.
  31. G. S. Achliya, S. G. Wadodkar, A. K. Dorley, Indian J. Exp. Biol., 2004, 42, 499.
  32. File SE, Wardill AG. The reliability of the holeboard apparatus.Psychopharmacologia. 1975;44:47-51.
  33. Rushton R, Steinberg H and TinsonC.Modification of the effects of an Amphetamine barbiturate mixture by the past experience of rats (Y-shaped Runway). Nature.192: 533-535 (1961).
  34. Dunham NW, Miya TS, A note on simple apparatus for detecting neurological deficit in rats and mice, J. Am. Pharm., 1957, 46, 208.
  35. Randal P, Studies of neurological effects using a simple experimental model, J. Pharmacol. Exp. Ther, 1960, 135, 543.
  36. Guillemain, J. and M. Tetau, 1980. Contribution à l’étude d’un “tranquillisantvégétal” Tiliatomentosa Bourgeons. Cahiers de Biothérapie, 68: 1-8.
  37. Goyal M, Nagori BP, asmal D. sedative and anticonvulsant effects of an alcoholic extract of Capparisdeciduas. J Nat Med 2009; 108: 491-5.
  38. Bhattacharya S K, Sanyal AK. Inhibition of Pentalenetetrazolinduced convulsions in rats by prostaglandin E1: role of brain monoamines. Psychopharmacology 1978; 56: 235-237.
  39. Gerhard Vogel H, Wolf gang H. Drug discovery and evaluation pharmacological assays. 2nd ed., New York: Springer,Verlag Berlin Heidelberg publisher; 2002. p. 487- 494.
  40. G. Griebel, G. Perrault, S. Tan, H. Schoemaker, and D. Sanger. Pharmacological studies on synthetic flavonoids: comparision with diazepam, Neuropharmacol 1999; 38: 965-977.
  41. Fastier FN, Spenden RN, Hendrieka W, Prolongation of chloral hydrate sleeping time by 5- HT and by certain other drugs, Br. J. Pharmacol., 1957,12, 251.
  42. Mukharjee PK, Saha K, Balasubramanium R, Pal M., Saha BP, Studies of psychopharmacological effects of NelumbonuciferaGaertn. Rhizome extract. J. Ethnopharmacol, 1996, 54, 63.
  43. C. A. Lowery, P. L. Johnson, A. Hay-Schmidt, J. Mikkelsen, A. Shekhar, Stress, 2005, 8, 233.
  44. Johnston, G.A.R. 2005. GABAA Receptor Channel Pharmacology.Curr.Pharmaceut.Design, 11: 1867- 1885.
  45. Ross and Wilson, Anatomy and Physiology in Health and illness, 9th ed.., (Churchill Livingstone, New York), 2001, 151.
  46. Curtis, D.R., Duggan, A.W., Felix, D., Johnston, G.A.R, McLennan, H., (1971): Antagonism between bicculline and GABA in the cat brain. Brain Res., 33: 57-73.
  47. Meldrum, B.S., (1975): Epilepsy and gammaaminobutyric acid. Int. Rev. Neurobiol., 17: 1-36.
  48. Tortora GJ and Grabowski SR, Principle of Anatomy and Physiology, 10th ed., (John Wiley and Sons, USA), 2003, 473.

Author Info

 

Copyright:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

iomcworld scan

Journal Highlights

Journal Flyer

Flyer